Fusion of hC3d3 to hCGβ enhances responsiveness in vitro of human peripheral immunocompetent cells upon the antigen primary challenge
Hua-Ping Li,Xiao-Ju He,Chuan-ling Tang,Xiao-Ying Yao,Da-Jin Li
DOI: https://doi.org/10.1016/j.jri.2008.03.004
IF: 3.993
2008-01-01
Journal of Reproductive Immunology
Abstract:Contraceptive vaccines based on hCGβ have not met clinical application because of poor immunogenicity. In the present study, the eukaryotic expression vectors pCI-gs-signal-6His-hCGβ and pCI-gs-signal-6His-hCGβ-hC3d3 were constructed, and transfected into CHO cells with aid of Lipofectaine 2000 reagent to gain the secretory recombinant protein. Isolated B cells from human peripheral blood, combined B cells with T cells, and PBMC were treated in vitro, respectively, with 1nM, 10nM, 100nM hCGβ, hCGβ-hC3d3 or PWM for 12 days. Immunoglobulin (Ig) and anti-hCG antibody levels in the supernatant were measured by an indirect enzyme-linked immunosorbent assay (ELISA). The expressions of CD80/CD86 on B cells, and CD154/CD25 on T cells, were analyzed by flow cytometry (FCM), and IL-2 production was assayed by ELISA. It was found that the Ig levels in the B-cell supernatants, the combined B with T cells, and PBMC treated with 100nM hCGβ-C3d3 fusion protein were 4-fold, 10-fold and 10.9-fold more, respectively, than that of hCGβ. The anti-hCG antibody could be produced in the combined B cells with T cells, as well as PBMC challenged with 100nM hCGβ-C3d3, but no anti-hCG antibody was produced in the challenge with hCGβ. The hCGβ-hC3d3 fusion protein enhanced the expression of CD80 and CD86 on B cells, especially CD86 (P<0.05), and significantly increased the expression of CD154 and CD25 molecules on T cells compared to that of hCGβ (P<0.05). The hCGβ-hC3d3 promoted human PBMC producing more IL-2 than hCGβ. These findings indicate that the fusion of hC3d3 to hCGβ, as a means of harnessing the adjuvant potential of the innate immune system, may contribute to a more efficient humoral immune response, and might provide a potential application of protein vaccine strategies in humans in the future.